All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort studyResearch in context

Background: All-cause and AIDS-mortality in Europe has been decreasing between 1996 and 2020. However, regional differences as well as their drivers remain unclear. This study investigates mortality differences and their drivers, including usage of and response to antiretroviral therapy (ART) and ac...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet regional health. Europe 2024-09, Vol.44, p.100989
Main Authors: Christian Kraef, Erich Tusch, Sabine Singh, Lars Østergaard, Gerd Fätkenheuer, Antonella Castagna, Santiago Moreno, Katharina Kusejko, Bartosz Szetela, Anastasiia Kuznetsova, Janez Tomažič, Jovan Ranin, Robert Zangerle, Fredrik Mansson, Giulia Marchetti, Stéphane De Wit, Amanda Clarke, Jan Gerstoft, Daria Podlekareva, Lars Peters, Joanne Reekie, Ole Kirk
Format: Article
Language:English
Subjects:
AIDS
Eastern Europe
Europe
HIV
Mortality
Tuberculosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: All-cause and AIDS-mortality in Europe has been decreasing between 1996 and 2020. However, regional differences as well as their drivers remain unclear. This study investigates mortality differences and their drivers, including usage of and response to antiretroviral therapy (ART) and active tuberculosis (TB), among people with HIV across Europe. Methods: People with HIV enrolled in EuroSIDA were followed from 2001 through 2020. Immunologic-virologic status (IVS) was categorized as poor (CD4-cell count ≤350 cells/mm3 and viral load (VL) > 200 copies/ml), good (CD4 ≥ 500 and VL 
ISSN:2666-7762